Heightened Activity of Specific Brain Cells Following Traumatic Social Experience Blocks Social Reward and Promotes Sustained Social Avoidance
Past social trauma is encoded by a population of stress/threat-responsive brain cells that become hyperactivated during subsequent interaction with non-threatening social targets. As a consequence, previously rewarding social targets are now perceived as social threats, which promotes generalized social avoidance and impaired social reward processing that can contribute to psychiatric disorders, according to a study conducted by researchers at the Brain and Body Research Center at Mount Sinai and published November 30 in Nature.
In humans, studies have shown that social trauma impairs brain reward function to the extent that social interaction is no longer rewarding, leading to severe social avoidance. In rodents, chronic social defeat stress, a model of social trauma, has been used to understand the brain circuit mechanisms underlying stress susceptibility versus resilience, yet little is known regarding its impact on social reward. Previous studies have assessed social interaction with an adult mouse similar to those used as aggressors to induce the social trauma. Social avoidance under these circumstances likely reflects fear or submissive behavior, rather than altered social reward.
“To better understand how traumatic social experience affects social reward, we tested social interaction and social preference with a same-sex juvenile mouse that, under control conditions, is rewarding,” said Long Li, PhD, Instructor of Neuroscience at the Icahn School of Medicine at Mount Sinai and lead author of the study. “We found that, following chronic social defeat stress, a subset of male and female mice termed susceptible avoid social interactions with juvenile mice and do not develop context-dependent social reward following encounters with them.”
In the study, adult male and female mice underwent chronic social defeat stress, in which they were repeatedly subordinated by aggressive mice, followed by social interaction testing, where an experimental mouse is placed in a cage with a larger aggressive mouse behind a barrier and the amount of time spent interacting is measured. The mice were classified as resilient or susceptible to the stressor based on their social interaction behavior. This was followed by an additional social interaction test called resident-intruder test in which a 4-6-week-old (juvenile) same-sex mouse was introduced into the subjects’ homecage and allowed to freely interact. This was then followed by a social conditioned place preference test in which the subject mice were conditioned with the juvenile mice to assess their preference for rewarding social targets. During the resident-intruder test, control and resilient mice exhibited similar social behaviors towards the juvenile, including the amount of active interaction (approach, close following, and sniffing). Mice in these groups rarely withdrew from social contact with the juvenile and freely approached and investigated them. Conversely, stress-susceptible mice exhibited much less active social investigation, a longer delay before the first social bout (“latency”), and significantly more social avoidance. Furthermore, social investigation time, social avoidance, and latency to investigate correlated with social interaction ratios during testing with an aggressive adult mouse. These results show that susceptible mice not only exhibit avoidance towards aggressive adult male mice, but also to non-threatening same-sex juvenile mice.
To identify the potential brain regions involved in heightened social threat, advanced histological and imaging techniques were used to identify a population of stress/threat responsive lateral septum neurotensin (NTLS) neurons that are activated by juvenile social interactions only in susceptible mice, but not in resilient or unstressed control mice.
Lastly the team used optogenetic and chemogenetic strategies to either activate or inhibit NTLS neurons and their downstream connections.
“What was so surprising is that when NTLS neurons were activated in a social threat context, they inhibited centers in the brain that encode information about social rewards,” said Scott Russo, PhD, Professor of Neuroscience and Director of the Center for Affective Neuroscience and Brain Body Research Center. “So ultimately we believe that when mice experience social trauma their ability to experience social reward is occluded by these NTLS cells.”
These findings provide an important foundation for understanding the neural mechanisms underlying post-trauma social reward processing. The Mount Sinai team is planning studies in humans to test the relevance of lateral septum circuitry in mediating social threat perception and reward sensitivity in victims of trauma.
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.
Ranked 14th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators and clinicians work within and across 34 academic departments and 35 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases.
Icahn Mount Sinai offers highly competitive MD, PhD, and Master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System.
A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into healthcare products and services that benefit the public.
Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs.
Through the Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.
The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.
* Mount Sinai Health System Member Hospitals: The Mount Sinai Hospital; Mount Sinai Queens; Mount Sinai Beth Israel; Mount Sinai West; Mount Sinai Morningside; Mount Sinai Brooklyn; New York Eye and Ear Infirmary of Mount Sinai; and Mount Sinai South Nassau
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties.